The metabolic advantage given by VDAC1 overexpression to cancer cells is due to the fact that it presents binding sites for overexpressed Hexokinase, allowing direct transport of mitochondrial ATP for glucose phosphorylation, thus increasing the glycolytic rate, a characteristic of cancer cells (i.e., the Warburg effect). The gene discussed is VDAC1; the disease is cancer.